Targets › SNAP25
15 programs from 14 companies in 63 trials: 22 Phase 2, 19 Phase 4, 17 Phase 3, 5 Phase 1; Other, Neurology, Immunology; next expected readout Nov 2026.
t-SNARE involved in the molecular regulation of neurotransmitter release. May play an important role in the synaptic function of specific neuronal systems. (UniProt, P60880)
Open in Phaseline: the race on SNAP25, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Johns Hopkins University | Abobotulinumtoxina Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor | SNAP25 | Phase 4 | Adolescent Idiopathic Scoliosis | Dec 2026 |
| Universidade Federal Fluminense | AbobotulinumtoxinA Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor | SNAP25 | Phase 4 | Spastic Paraplegia | Feb 2027 |
| Montefiore Medical Center | Daxibotulinumtoxina Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor | SNAP25 | Phase 4 | Benign Essential Blepharospasm | Mar 2027 |
| AbbVie | OnabotulinumtoxinA Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor | SNAP25 | Phase 4 | Jawline and Neck Appearance; Urinary Bladder, Overactive; Overactive Bladder; Trigeminal Neuralgia … | Jun 2027 |
| Ipsen | Botulinum Toxin Type A Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme | SNAP25 | Phase 3 | Chronic Migraine; Episodic Migraine; Obstructed Defaecation Syndrome; Rhizarthrosis … | Nov 2026 |
| Merz Therapeutics | Incobotulinumtoxina Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor | SNAP25 | Phase 3 | Chronic Migraine; Episodic Migraine; Fissure in Ano; Stroke … | Mar 2027 |
| Merz Pharmaceuticals | Incobotulinumtoxina Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor | SNAP25 | Phase 3 | Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury | Apr 2027 |
| Huons Biopharma | HU-045 Botulinum toxin type A; cleaves SNAP25 to block acetylcholine release at the neuromuscular | SNAP25 | Phase 3 | Glabellar Lines | May 2027 |
| Merz Aesthetics | Incobotulinumtoxina Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor | SNAP25 | Phase 3 | Neuromuscular Agents | Aug 2027 |
| Merz North America | Incobotulinumtoxina Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor | SNAP25 | Phase 3 | Neuromuscular Agents | Sep 2027 |
| Henry Ford Health System | Abobotulinumtoxina Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor | SNAP25 | Phase 2 | Scar | Dec 2026 |
| AbbVie | Trenibotulinumtoxine (AGN-151586) Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme | SNAP25 | Phase 2 | Forehead Lines; Upper Facial Lines; Glabellar Lines | Feb 2027 |
| All India Institute of Medical Sciences | Botulinum Toxin Type A Injection [Botox] Botulinum toxin A injection into cricopharyngeus muscle to reduce muscle hypertonia and im | SNAP25 | Phase 2 | Transfer Dysphagia | Aug 2027 |
| University of Pennsylvania | Daxibotulinumtoxina Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor | SNAP25 | Phase 2 | Blepharospasm of Both Eyelids | Jun 2028 |
| Biojiva | Botulinum Toxin Type A (RT001) Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme | SNAP25 | Phase 2 | Infantile Neuroaxonal Dystrophy | – |
Chronic Migraine (3) Overactive Bladder (3) Episodic Migraine (2) Stroke (2) Glabellar Lines (2) Neuromuscular Agents (2) Infantile Neuroaxonal Dystrophy (1) Fissure in Ano (1) Focal Hand Dystonia (1) Peripheral Neuropathy Due to Chemotherapy (1) Androgenetic Alopecia (1) Provoked Vestibulodynia (1)
protein or peptide (11), small molecule (3), mixed (1)
AbbVie (2) Biojiva (1) Merz Therapeutics (1) Ipsen (1) All India Institute of Medical Sciences (1) Montefiore Medical Center (1) Huons Biopharma (1) Universidade Federal Fluminense (1) Johns Hopkins University (1) Merz Aesthetics (1) University of Pennsylvania (1) Merz Pharmaceuticals (1) Merz North America (1) Henry Ford Health System (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.